Cyclacel Pharmaceuticals, Inc.
(NASDAQ : CYCC)

( )
CYCC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.00%181.611.3%$472.14m
CELGCelgene Corporation
-0.46%96.701.3%$403.47m
ARRYArray BioPharma Inc.
0.17%46.668.1%$399.88m
GILDGilead Sciences, Inc.
0.00%68.200.9%$392.70m
BIIBBiogen Inc.
0.21%233.501.3%$355.43m
ILMNIllumina, Inc.
-0.39%346.483.5%$275.54m
REGNRegeneron Pharmaceuticals, Inc.
0.01%306.652.6%$226.84m
VRTXVertex Pharmaceuticals Incorporated
2.39%177.941.9%$204.61m
AAgilent Technologies, Inc.
0.03%71.911.6%$200.95m
EXASExact Sciences Corporation
1.12%117.0024.1%$190.71m
ALXNAlexion Pharmaceuticals, Inc.
1.86%122.372.0%$177.80m
BMRNBioMarin Pharmaceutical Inc.
1.59%85.514.3%$129.52m
SRPTSarepta Therapeutics, Inc.
0.56%133.0614.7%$105.93m
INCYIncyte Corporation
0.59%84.782.5%$104.85m
MRTXMirati Therapeutics Inc.
-2.25%99.992.5%$98.50m

Company Profile

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.